OTC Healthcare in Slovenia
Euromonitor International's OTC Healthcare in Slovenia market report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, packaging innovations, economic/lifestyle influences, distribution or pricing issues. Forecasts illustrate how the market is set to change.
Get immediate access to strategic market analysis when you buy reports online
Tables: 13 | Publication date: Mar 2007
Why buy this report
- Get insight into trends in market performance
- Pinpoint growth sectors and identify factors driving change
- Identify market and brand leaders and understand the competitive environment
Product coverage
Adult mouthcare; Allergy care; Analgesics; Calming and sleeping products; Child-specific OTC healthcare; Cough; cold and allergy (hay fever) remedies; Digestive remedies; Ear care; Emergency contraception; Eye care; Medicated skin care; NRT Smoking cessation aids; OTC obesity; OTC statins; Vitamins and dietary supplements; Wound treatments
Executive summary
Small size of OTC healthcare market discourages new entrants and product developments
With only two million inhabitants, Slovenia’s OTC healthcare market is relatively small. It is difficult for new entrants to gain entry to the market, for a number of reasons. These include strict regulations, the high cost of attaining marketing authorisation and running advertising campaigns for both public and medical professionals, a heavily subsidised social healthcare system and fierce competition. During the review period, this environment was not conducive to new product developments. Leading companies instead focused their efforts on maintaining or strengthening their market positions.
Monopolistic position of chemists/pharmacies outlets is threatened by regulatory changes
On 20 January 2006, the Slovenian government announced that certain OTC healthcare products were to be made available in mainstream retail outlets. Prior to this, only vitamins and dietary supplements products could be sold in retail outlets, while the distribution of all other OTC healthcare products was limited to chemists/pharmacies and drugstores/parapharmacies outlets. The Slovenian Chamber of Pharmacy Pharmacists fought against the proposed regulatory changes, as they threatened their monopolistic position, but without success. On 7 March 2006, the government introduced legislation allowing the distribution of more OTC healthcare products in mainstream retail outlets. However, exactly what types of OTC healthcare products will benefit from this wider distribution will not become clear until later in the forecast period.
Domestic players Krka and Lek Pharmaceuticals continue to benefit from first mover status
Krka dd and Lek Pharmaceuticals dd, both of which produce generics products, were the leading players within Slovenian OTC healthcare in terms of current value sales in 2005. Moreover, they occupied leading positions in most individual OTC healthcare sectors, thanks to their long-standing traditions in the country. When they were initially established, Slovenia was not open to foreign companies; thus both players continued to benefit from first mover advantages in 2005. Among Krka’s most important OTC healthcare brands are Septolete and Pikovit, while those of Lek include Lekadol and Persen. Both companies successfully defended the market value shares of these brands throughout the review period.
Distribution changes could impact negatively on constant value sales over 2005-2010
All chemists/pharmacies outlets in Slovenia are subsidised by the state. Prior to and during the review period, this meant that these outlets enjoyed a near-monopoly position in terms of the distribution of OTC healthcare products. However, this will no longer be the case when the regulatory changes announced in 2006 are finally implemented over the forecast period. Certain OTC healthcare products will become available at cheaper prices in mainstream retail outlets, and this is likely to have a negative effect on constant value sales. Specifically, industry analysts suggest that greater competition between retail operators will lead to a fall of around 10% in OTC healthcare unit prices.
Table of contents
OTC HEALTHCARE IN SLOVENIA : MARKET INSIGHT
EXECUTIVE SUMMARY
OPERATING ENVIRONMENT
OTC Registration and Classification
Vitamins & Dietary Supplements Registration and Classification
Advertising
Packaging and Labelling
Distribution
De-listing or De-reimbursement
Traditional Remedies
Homeopathy
Generics
Consumer Expenditure on Health Goods and Medical Services
Table 1 Consumer Expenditure on Health Goods and Medical Services 2000-2005
Life Expectancy
Table 2 Life Expectancy at Birth 2000-2005
OTC HEALTHCARE SALES
Market Performance
Table 3 Retail Sales of OTC Healthcare by Sector: Value 2000-2005
Table 4 Retail Sales of OTC Healthcare by Sector: % Value Growth 2000-2005
Switches
Competitive Environment
Table 5 OTC Healthcare Company Shares by Retail Value 2001-2005
Table 6 OTC Healthcare Brand Shares by Retail Value 2002-2005
Leading Company Profile: Krka dd
Summary 1 Krka dd: Operational Indicators 2004
Leading Company Profile: Lek Pharmaceuticals dd
Summary 2 Lek Pharmacuticals dd: Operational Indicators 2004
New Product Developments
Summary 3 OTC Healthcare: New Product Launches 2004-2005
Retail Distribution
Table 7 Retail Sales of OTC Healthcare by Distribution Format: % Analysis 2000/2005
Table 8 Retail Sales of OTC Healthcare by Sector and Distribution Format: % Analysis 2005
Retailer Activity and Private Label Trends
Forecast Market Performance
Table 9 Forecast Retail Sales of OTC Healthcare by Sector: Value 2005-2010
Table 10 Forecast Retail Sales of OTC Healthcare by Sector: % Value Growth 2005-2010
DEFINITIONS